Evotec SE

    Jurisdiction
    Germany
    LEI
    529900F9KI6OYITO9B12
    ISIN
    US30050E1055 (EVO)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - Specialty & Generic

    Scores

    InsiderPie Expert Score
    trending_flat 54 / 100
    Better than peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    4 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €777.33M
    Gross margin
    12.9%
    EBIT
    -€67.49M
    EBIT margin
    -8.7%
    Net income
    -€155.53M
    Net margin
    -20.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €734.13M -5.6% -€16.59M -89.3%
    €804.22M +9.5% €26.71M -261.0%
    €855.71M +6.4% €64.93M +143.1%

    Dividends

    Last dividend amount
    $0.29
    Ex date

    Add to watchlist

    Notifications